← Back to Search

Other

CP-609,754 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No other serious concurrent systemic disorders that would preclude study, No uncontrolled diabetes mellitus, thyroid disease, or seizure disorder, No active neurologic or psychiatric disease, No clinically apparent uncontrolled infection (e.g., HIV, hepatitis B or C), No known sensitivity to imidazole containing drugs (e.g., clotrimazole, oxiconazole, sulconazole, econazole, etoconazole, metronidazole, or ketoconazole), No clinically significant gastrointestinal abnormalities requiring intravenous alimentation, No malabsorption syndrome or active peptic ulcer, No other lab abnormalities (i.e., electrolytes, uric acid, calcium, phosphorous, or glucose) that would preclude study, No other malignancy in past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the breast or cervix
Histologically or cytologically confirmed advanced solid tumor with no standard curative therapy OR refractory OR disease progression while on therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well CP-609,754 works in treating patients with advanced solid tumors.

Who is the study for?
Adults with advanced solid tumors that can't be cured or have gotten worse despite treatment. They must not have brain metastases, serious heart conditions, uncontrolled infections like HIV/Hepatitis B/C, certain gastrointestinal issues, or a recent history of stroke. Pregnant/nursing women and those not using effective contraception are excluded.Check my eligibility
What is being tested?
The trial is testing the effectiveness of CP-609,754 in patients with advanced solid tumors. It's a Phase I study which means it's early in the clinical trials process and primarily looking at how safe the drug is and what dose might be best.See study design
What are the potential side effects?
Since this is a Phase I trial for CP-609,754, specific side effects aren't listed but may include typical chemotherapy-related reactions such as fatigue, nausea, blood count changes leading to increased infection risk or bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My advanced cancer has no cure, is resistant to treatment, or is getting worse despite therapy.
Select...
My liver function tests are within the required range.
Select...
I am 18 years old or older.
Select...
My cancer has not spread to my brain or its coverings.
Select...
I am able to get out of my bed or chair and move around.
Select...
I haven't had strokes, serious heart issues, or heart attacks in the last 6 months.
Select...
My kidney function, measured by creatinine levels or clearance, is within the required range.
Select...
I haven't been hospitalized for COPD in the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
537 Previous Clinical Trials
134,991 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,646 Total Patients Enrolled
Daniel M. Sullivan, MDStudy ChairH. Lee Moffitt Cancer Center and Research Institute
2 Previous Clinical Trials

Media Library

CP-609,754 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00006085 — Phase 1
Solid Tumors Research Study Groups:
Solid Tumors Clinical Trial 2023: CP-609,754 Highlights & Side Effects. Trial Name: NCT00006085 — Phase 1
CP-609,754 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006085 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this particular remedy have the full endorsement of the FDA?

"The current clinical data on this treatment's safety is rather limited, and thus it was ascribed a score of 1. This evaluation process took place during the trial's Phase 1 stage."

Answered by AI

Has the enrollment period for this research project been closed off yet?

"As of today, clinicaltrials.gov states that this particular experiment is no longer accepting participants - the original post date was June 1st 2000 and it last received updates on December 18th 2013. Despite its inactivity, there are still 2408 other trials recruiting patients at present."

Answered by AI
~14 spots leftby Mar 2025